Background and Objectives Platelet transfusions are widely administered to restore perioperative haemostasis in haemorrhagic patients; however, the role of platelet transfusion is not well understood and administration is often based on empiric data. This review aims to explore consensus regarding platelet transfusion trigger, dose and how the haemostatic efficacy of platelet transfusion was assessed for the treatment of perioperative bleeding.
Introduction
The management of bleeding following trauma or surgical procedures is an important consideration. In the perioperative patient population, coagulation changes occur due to multiple physiologic, pathologic and/or pharmacologic agents that collectively affect haemostasis [1] . Platelets are a critical component of coagulation and fibrin clot formation [2, 3] , and the increasing use of antiplatelet agents, including aspirin, P2Y12 receptor antagonists (clopidogrel, prasugrel or ticagrelor), significantly influence perioperative haemostasis [4, 5] .
Platelet transfusions have been considered to be a principal approach to restoring haemostasis in haemorrhagic patients where low platelet number or function is a major contributor to bleeding [2] . Platelet transfusion is often based on platelet numbers as most platelet function assays have not been systematically evaluated in a bleeding patient and may require a platelet count of at least 100 9 10 9 /l. Platelet transfusions may be associated with a number of adverse outcomes, including longer hospital stays, more postoperative ventilation, increased risk for postoperative infection and transfusion-related acute lung injury [2, 6, 7] , although platelet transfusion may be a surrogate marker for sicker patients rather than having a direct causal link [8] . A review of transfusion-related viral transmission suggested that sepsis from a bacterially contaminated platelet unit represents the most frequent infectious complication from any blood product today [6, 7, 9] . Additionally, platelet transfusions are associated with substantial costs [10, 11] . As a result, it is important to ensure that objective data for platelet transfusions are carefully considered to avoid exposing the patient to unnecessary risks and costs. Managing patients in the perioperative setting depends on the type of injury, risk of bleeding and other potential confounding details. Although the critical threshold for platelet counts or function in surgical patients is not currently known, guidelines for managing perioperative bleeding make recommendations for platelet transfusions [6, [12] [13] [14] [15] [16] . However, these recommendations are based mainly on consensus statements or expert opinions and not actual platelet function studies, and a considerable amount of the data are derived from haematological oncology patients [1, 17] .
As platelet function is vital for primary haemostasis, understanding the role of platelet transfusions and the critical threshold for transfusion is important. A systematic review has previously been carried out regarding the appropriate indications and optimal threshold for platelet transfusion in a variety of settings [18] . We decided to perform an additional evaluation, with the aim of critically reviewing the current data in order to identify the appropriate role of platelet transfusions in the management of perioperative haemostasis. In particular, we wished to focus on whether there is consensus regarding the trigger for transfusion, the dose to be administered, and how the haemostatic efficacy of platelet transfusion should be assessed.
Methods
A literature search was conducted using MEDLINE (PubMed) on 28 March 2017, with the objective of identifying original, English language articles which reported on research regarding the use of platelet transfusion for perioperative haemostasis. The following search string was used: ['platelet transfusion' (Title) OR 'platelet transfusions' (Title)].
All publications retrieved were individually assessed against predefined exclusion and inclusion criteria (listed below). Obvious irrelevant publications were excluded, and other publications were discussed between two individuals to agree on the eligibility and reasons for exclusion.
All publications were subjected to an initial screen based on the title and abstract. The aim of the review was to assess consensus regarding platelet transfusion triggers and dose, and how the haemostatic efficacy of these transfusion strategies was evaluated, rather than comparing patient outcomes between publications. As such, the inclusion criteria included the description of platelet transfusion as the studied intervention to stop bleeding, patients described as actively bleeding or presenting with coagulopathic bleeding and publications reporting on the haemostatic effect of platelet transfusion on patient outcomes (e.g. bleeding, incidence of transfusion with other blood products, coagulation status.), in particular, those looking at triggers or dose. Exclusion criteria included: articles in non-English language; non-original clinical studies (e.g. reviews, study protocols, conference abstracts, letters, meta-analyses); no end-points included that provided information regarding the haemostatic efficacy of platelet transfusion (e.g. papers reporting only on safety were excluded); healthy patients; patients with congenital or malignant disorders; neonates; publications not focused on perioperative bleeding management; publications where platelet transfusion was not the focus of the study; publications where platelet to red blood cell ratios are being compared (as these studies are not focusing on assessing platelet transfusion); and publications looking at other aspects of platelet transfusion (e.g. comparing washed with non-washed platelets).
A second screen was then undertaken using the same inclusion/exclusion criteria, by reviewing the full text of the publications, prior to extracting the data regarding study type, patient age, disease setting, platelet count and dose, trigger for transfusion and the end-point of the study. The study subjects, authors, methods and time periods for each article were examined in order to avoid inclusion of redundant data from multiple reports.
Results
The search produced 1181 results, and these were individually assessed for inclusion in our review (see Fig. 1 for flow diagram). The search identified studies carried out in a variety of settings, with both prophylactic and therapeutic platelet transfusion. Only one publication regarding paediatric patients was identified by our search criteria; it was therefore decided to focus this review on adult patients. Eight publications reporting on platelet transfusion with respect to trigger, dose and assessing the effect on bleeding in perioperative patients were identified (Table 1 ).
The majority (75%) of studies were retrospective, and the remainder were prospective. The most common setting was cardiac surgery (5 publications, 63%), followed by mixed medical/surgical settings, liver transplant and trauma (1 publication each).
A high degree of variability was observed in the published studies. Only half the publications specified a trigger for platelet transfusion; triggers used included platelet count, bleeding and thromboelastometry measurements. The trigger most commonly used was platelet count (in two publications, 25%), either on its own or in conjunction with other factors such as incidence of bleeding. The platelet counts used as triggers varied between the two publications, ranging from a median of 41 (IQR 20-57) 9 10 9 /l for prophylactic treatment in a study evaluating patients in a mixed medical/surgical intensive care unit [19] to a trigger of <100 9 10 9 /l accompanied by bleeding in cardiac surgery patients [20] . A diverse range of platelet doses was administered, with the quantity most commonly measured as number of units (five publications, 63%). Publications reporting the number of units given per transfusion quoted figures ranging from 1 unit [20, 21] to 6-12 units [22] . Even the methods used to assess the haemostatic effectiveness of platelet administration differed, with end-points including incidence or quantity of transfusion with other blood products (five publications, 63%), the incidence or severity of bleeding (three publications, 38%) and/or measurement of haemostatic variables, including platelet count response (three publications, 38%) among the outcome measures. The methods used to assess bleeding, either as a trigger or as an outcome measure, were also variable, including incidence of bleeding, bleeding volume, percentage of bloodless surgery or bleeding time.
Discussion
Platelet transfusion is a critical therapy when restoring haemostasis in haemorrhagic patients, and objective data are needed to assure appropriate decision-making due to both costs and risks of transfusions [2] . However, what constitutes appropriate use of platelet transfusion remains a controversial issue; significant variability occurs in managing bleeding and perioperative transfusion practices, and many centers do not follow available guidelines [23, 24] . This finding is confirmed by the variability A variety of end-points were used to assess the haemostatic efficacy of platelet transfusion in the studies identified. Although incidence and/or quantity of transfusion with other blood products was the most common outcome assessed, some of the studies instead focused on the incidence and/or severity of bleeding to determine the haemostatic efficacy of platelet transfusion. The methods used to assess bleeding varied and included measures such as volume of blood loss, bleeding time and incidence of bleeding events. However, the use of bleeding as an outcome measure may be problematic, with potential issues such as the subjective interpretation of bleeding scales and the possibility that using the World Health Organization (WHO) bleeding of Grade 2 or higher fails to meet the requirements of a valid surrogate and composite outcome [25] . Other outcome measures, such as patient survival or the cost of platelet transfusion to the healthcare system, could be used as alternatives (or in addition) to bleeding. The dose administered in each study also varied, in both the quantity administered, and in how the dose was reported.
Current guidelines recommend measuring platelet count before transfusing with platelets [6, 12, 14, 16, 26] . Although 25% of the publications reviewed here used platelet count as a trigger for platelet transfusion, a range of values was used to define the trigger. However, there are concerns regarding the accuracy of automated platelet counting in thrombocytopenic blood samples [27] . Instead, the patient's platelet function may be a more important factor than platelet count when considering whether transfusion is required, for example following surgery a patient may have a high platelet count, but still be at risk of bleeding due to platelet dysfunction. This is also supported by the finding from a large retrospective study that platelet count is a poor predictor of bleeding in thrombocytopenic oncology patients [28, 29] . Although laboratory platelet function tests may provide a more accurate trigger for transfusion, they are time-consuming, require special resources, may not be reliable at low platelet counts and are not validated for use in bleeding patients [30, 31] . Additionally, it is unclear which patients may benefit from routine perioperative testing of platelet function [31] , and it can be difficult to measure platelet function in perioperative settings, as most functional assays require a critical platelet mass. An alternative could be to guide and monitor platelet transfusion using point-of-care testing, such as point-of-care platelet function testing (e.g. using analysers such as the Multiplate TM A review of platelet transfusion regarding the appropriate indications and optimal threshold for transfusion in various settings was recently reported by Kumar et al., [18] who performed a systematic review of 17 randomized controlled trials and 55 observational studies. They noted results from observational studies showed no evidence that platelet transfusion prevented significant bleeding in patients undergoing central venous catheter insertions, lumbar puncture or other surgical procedures; however, the methodologic quality of observational studies was low. Compared to our analysis, the review from Kumar et al. makes recommendations on specific points based on a systematic review and focuses on thrombocytopenia. An evidence-based review of platelet transfusion in critical care and surgery has also recently been published by Etchill et al. [35] . This review concurred with our findings of a wide variety in platelet transfusion practices, despite the high utilization of platelet transfusion in critically ill and surgical populations, and highlighted the lack of evidence-based guidelines.
Due to the potential adverse events and costs associated with platelet transfusion, it may be advisable to consider alternative treatments for coagulopathic perioperative patients. Targeted algorithms to treat bleeding recommend the administration of specific haemostatic agents, such as fibrinogen supplementation with cryoprecipitate or fibrinogen concentrate, prothrombin complex concentrate, Factor XIII or FVII, as well as allogeneic blood products [36] [37] [38] . Based on studies utilizing these algorithms, guidelines for the management of severe perioperative bleeding recommend the use of transfusion algorithms incorporating predefined intervention triggers to guide haemostatic intervention, as these may reduce transfusion requirements, improve outcomes and lower costs [26] . Additionally, laboratory and clinical studies have shown that reduced clot firmness and increased bleeding resulting from diminished platelet count may be partially compensated for by fibrinogen supplementation [39, 40] . The same effect has been observed when blood samples from patients undergoing cardiopulmonary bypass were supplemented with fibrinogen concentrate and/or recombinant activated factor VII [41] .
Our analysis focuses on perioperative haemostasis, considers a variety of platelet transfusion triggers and focuses on the actual perioperative and surgical perspectives. A potential limitation of our review is that it is not a fully comprehensive systematic review. Our search criteria were restrictive in order to identify the most relevant publications, and we only considered English language articles available via PubMed. As such, a full systematic review utilizing additional databases may have identified further relevant publications. Additionally, the wide variety of methods, triggers and outcomes reported in the publications reviewed here left us unable to draw clear conclusions regarding current practice in platelet transfusion. Ongoing systematic reviews of the efficacy of platelet transfusion and proposed transfusion triggers and dose in oncology settings may provide useful guidance but will still leave many questions unanswered in the perioperative field [42] [43] [44] [45] .
Platelet transfusion is an important facet of haemostatic management. However, the high degree of variation in the methods and outcomes of the published studies evaluated in this review make it difficult to draw conclusions as to recommendations for platelet transfusion, as no clear consensus was identified. Due to the risks and costs associated with platelet transfusions, specific guidelines and/or algorithms are needed to ensure they are appropriately administered, and in appropriate doses. We conclude that there is a clear and urgent need for additional studies to assess the appropriate dose and triggers for platelet transfusion in perioperative patients and to investigate the suitability of current platelet transfusion guidelines in perioperative patients. plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. Transfusion 2010; 50: [487] [488] [489] [490] [491] [492] 
